| Name | Lodenafil |
| Description | Lodenafil (Hydroxyhomosildenafil) is a potent PDE5 inhibitor, with treatment of erectile dysfunction (ED) |
| Animal Research | Thirty male Sprague-Dawley rats were randomly divided into three groups: control; monocrotaline (experimental model); and lodenafil (experimental model followed by lodenafil treatment, 5 mg/kg daily for 28 days) Mean pulmonary artery pressure (mPAP) was obtained by right heart catheterization[1]. |
| In vivo | Investigated right ventricular hypertrophy (RVH) and IL-1 levels in lung fragments. The number of cases of RVH was significantly higher in the monocrotaline group than in the lodenafil and control groups, as were mPAP and IL-1 levels. Lodenafil can prevent monocrotaline-induced PH, RVH, and inflammation[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (9.91 mM), Sonication is recommended. DMSO : 250 mg/mL (495.44 mM), Sonication is recommended.
|
| Keywords | Phosphodiesterase (PDE) | phosphodiesterase | PDE | Lodenafil | Inhibitor | inhibit |
| Inhibitors Related | Balipodect | Theophylline monohydrate | D(+)-Raffinose pentahydrate | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | Icariin | Theophylline | Vardenafil hydrochloride | Sildenafil citrate | Doxofylline |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library |